Keryx Biopharmaceuticals Inc., of Boston, reported first-quarter net U.S. Auryxia (ferric citrate) sales of $10.5 million, compared to $5.6 million in the first quarter of 2016, with the number of prescriptions for the hyperphosphatemia drug increasing about 72 percent year over year.